Scientific Sessions 2024  /  Atrial Fibrillation Ablation: Heart Failure, Myopathies and More  /  Hybrid Convergent Procedure as a ‘Bail Out’ Strategy In Patients with Atrial Fibrillation Resistant To Catheter Ablation
Logo

American Heart Association

  2
  0

Final ID: Sa2062

Hybrid Convergent Procedure as a ‘Bail Out’ Strategy In Patients with Atrial Fibrillation Resistant To Catheter Ablation

Abstract Body (Do not enter title and authors here): Introduction: Atrial fibrillation (AF) is a common and symptomatic arrhythmia which can be resistant to conventional endocardial catheter ablation. The Hybrid Convergent procedure, combining initial surgical AF ablation with a concurrent or staged endocardial catheter-based component, offers a potential solution for refractory cases. While effective as a de novo treatment for persistent AF, outcomes of this procedure in patients who failed prior catheter ablation remains uncertain. Our aim was to evaluate its efficacy and safety in this patient group.

Methods: We conducted a single-center retrospective cohort study involving consecutive patients selected for the Hybrid Convergent procedure between May 2019 and October 2022 at a single center in Perth, Western Australia. Eligible patients had symptomatic AF and failed prior catheter ablation and antiarrhythmic drugs. The primary outcome was single procedure freedom from atrial arrhythmias, on or off antiarrhythmic drugs at 12 months. Overall follow-up freedom from AF, 12-month AF burden, complications and reinterventions were also recorded.

Results: Sixty-two patients underwent both stages of the Hybrid Convergent procedure. All received concomitant thoracoscopic left atrial appendage exclusion. Of these, 46 (74.2%) were male, 27 (45.3%) had paroxysmal AF, and 15 (24.2%) had implantable loop recorders (ILRs). The mean duration since AF diagnosis was 9.5±7.1 years, with a median of 3 prior catheter ablations for AF. The median follow-up was 25.9 (13-48) months. After 12 months, 36 (62.9%) patients remained free from any atrial arrhythmia (figure 1). At this time point, 47 (75.8%) patients had an atrial arrhythmia burden of less than 5%. For the overall follow-up period, 32 (51.6%) patients maintained freedom from any atrial arrhythmia. Among patients with ILRs, the 12 month atrial arrhythmia free survival was 36.6%, compared with 64.4% in those without ILRs. Nine patients required repeat catheter ablation. There was one major complication.

Conclusions: Our initial experience with the Hybrid Convergent procedure demonstrates sustained effectiveness and safety for patients with paroxysmal or persistent AF who have previously failed catheter ablation strategies.
  • Spring, Remy  ( Sir Charles Gairdner Hospital , Nedlands , Western Australia , Australia )
  • Playford, Emma  ( University of Tasmania , Hobart , Tasmania , Australia )
  • Eranki, Aditya  ( St Georges Hospital , Sydney , Western Australia , Australia )
  • Joshi, Pragnesh  ( Sir Charles Gairdner Hospital , Nedlands , Western Australia , Australia )
  • Playford, David  ( University of Notredame , Fremantle , Western Australia , Australia )
  • Weerasooriya, Rukshen  ( University of Western Australia , Perth , Western Australia , Australia )
    • Author Disclosures:
    Remy Spring: DO NOT have relevant financial relationships | Emma Playford: DO NOT have relevant financial relationships | Aditya Eranki: No Answer | Pragnesh Joshi: No Answer | David Playford: DO have relevant financial relationships ; Research Funding (PI or named investigator):Edwards LifeSciences:Past (completed) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Echo IQ:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Expected (by end of conference) ; Research Funding (PI or named investigator):BMS:Past (completed) ; Research Funding (PI or named investigator):Pfizer:Past (completed) | Rukshen Weerasooriya: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Atrial Fibrillation Ablation: Heart Failure, Myopathies and More

Saturday, 11/16/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
A Hard Start: Early, Intensive Healthcare Utilization for Children with Critical Congenital Heart Disease

Ellis Danielle, Hall Matthew, Blume Elizabeth, Wolfe Joanne, Snaman Jennifer, Berry Jay

Adverse Events with Pulsed Field Ablation - A Review of the Food and Drug Administration’s Manufacturer and User Facility Device Experience Database

Cooper Julie, Zagrodzky William, Zagrodzky Jason, Omotoye Samuel, Sardana Mayank, Kaplan Andrew, Link Mark, Bunch Thomas, Daniels James

4138840_File000000.jpg
4138840_File000000.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available